CBLB502

A radioprotective agent

CaptionSynonyms

CBLB502

Drug Information
Image
Identifiers CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name		Chemical Data C H N O Molecular Weight

CBLB502 is a radioprotective agent developed to mitigate the harmful effects of ionizing radiation on human tissues. It is derived from a protein found in the bacterium Salmonella and has shown promise in protecting against radiation sickness.

Mechanism of Action

CBLB502 works by activating the Toll-like receptor 5 (TLR5) pathway. This activation leads to the production of cytokines and other protective molecules that help shield cells from radiation-induced damage. The primary target of CBLB502 is the gastrointestinal tract, which is highly susceptible to radiation.

Development and Research

The development of CBLB502 has been driven by the need for effective countermeasures against radiation exposure, particularly in the context of nuclear accidents and radiological terrorism. Preclinical studies have demonstrated its efficacy in animal models, and it has undergone various phases of clinical trials to assess its safety and effectiveness in humans.

Applications

CBLB502 is primarily intended for use in scenarios involving high levels of radiation exposure, such as during radiation therapy for cancer patients or in the aftermath of a nuclear disaster. It has the potential to significantly reduce the mortality and morbidity associated with acute radiation syndrome (ARS).

Related Pages

• Radiation therapy
• Radiation sickness
• Toll-like receptor
• Cytokine
• Nuclear disaster
• Radiological terrorism